Income StatementBalance SheetCash FlowSegments
Boston Scientific logo

Boston Scientific Balance Sheet Statement

Assets, liabilities, and shareholders' equity

Boston Scientific holds $44.4B in total assets. Cash and equivalents total $850.0M. The current ratio is 1.90. Based on the Q1 2026 filing.

Total Assets$44.4BTotal Stockholders Equity$25.9BLong Term Debt$11.6BCash And Equivalents$850.0MTotal Current Assets$8.7BTotal Current Liabilities$4.6B
Latest FilingQ1 2026
Report Date2026-05-01
Market Cap$85.9B
P/E Ratio24.13
ROE14.81%

Current Liabilities

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accounts payable$960.0M$1.0B$962.0M$1.0B$1.1B$1.1B
Other Commercial Liabilities$2.8B$2.4B$2.8B$3.0B$3.2B$2.5B
Accrued Liabilities, Current$2.8B$2.4B$2.8B$3.0B$3.2B$2.5B
Other accrued liabilities$887.0M$923.0M$952.0M$862.0M$795.0M$875.0M
Derivative Liabilities - Fair Value$990.0M$1.0B$1.4B$1.3B$1.3B$1.2B
Finance Lease Liability, Current————$1.0M—
Supplier Finance Program Obligations$140.0M$129.0M$139.0M$151.0M$144.0M$145.0M
Total current liabilities$6.4B$5.1B$5.2B$5.3B$5.4B$4.6B

Current Assets

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accounts receivable, net$2.7B$2.8B$2.9B$3.0B$3.1B$3.2B
Allowance for Doubtful Accounts$109.0M$113.0M$112.0M$133.0M$132.0M$127.0M
Cash and cash equivalents$364.0M$345.0M$388.0M$893.0M$965.0M$850.0M
Finished goods$1.8B$1.8B$1.8B$1.8B$1.8B$1.9B
Derivative Assets - Fair Value$384.0M$232.0M$91.0M$125.0M$181.0M$219.0M
Derivative assets$79.0M$11.0M——$181.0M$219.0M
Income taxes receivable$307.0M$294.0M$298.0M$310.0M$299.0M$358.0M
Raw materials$819.0M$843.0M$835.0M$849.0M$849.0M$928.0M
Work in process$193.0M$218.0M$218.0M$245.0M$246.0M$259.0M
Inventories$2.8B$2.9B$2.9B$2.9B$2.9B$3.1B
Prepaid expenses and other current assets$831.0M$756.0M$613.0M$701.0M$660.0M$729.0M
Restricted cash$111.0M$103.0M$109.0M$98.0M—$71.0M
Total current assets$6.9B$7.3B$7.1B$8.0B$8.8B$8.7B
Trading Securities in Marketable Securities$277.0M$297.0M$292.0M$310.0M$286.0M$396.0M

Non-Current Assets

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accumulated Goodwill Impairment Losses$9.9B$9.9B$9.9B$9.9B$9.9B$9.9B
Deferred Tax Assets and Other Non-Current Assets$1.8B$1.8B$1.9B$1.8B$1.9B$2.1B
Equity Method Investment Basis Difference—$374.0M$321.0M$375.0M—$334.0M
Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments$277.0M$297.0M$292.0M$310.0M$286.0M$396.0M
Goodwill$17.1B$17.3B$18.1B$18.2B$18.3B$18.5B
Indefinite-Lived Intangible Assets$94.0M$94.0M$813.0M$813.0M$813.0M$770.0M
Indefinite-Lived Intangible Assets, Gross$94.0M$94.0M$813.0M$813.0M$813.0M$770.0M
Indefinite-Lived Research and Development Assets$94.0M$94.0M$813.0M$813.0M$813.0M$770.0M
Indefinite-Lived Trademarks$94.0M$94.0M$813.0M$813.0M$813.0M$770.0M
Equity securities————$17.0M$16.0M
Investments - Amortized Cost Basis$277.0M$297.0M$292.0M$310.0M$286.0M$396.0M
Net Investment in Lease$449.0M$448.0M$492.0M$495.0M$465.0M$547.0M
Deferred tax assets$3.7B$3.7B$3.8B$3.7B$3.7B$4.0B
Other intangible assets—net$6.7B$6.6B$7.3B$7.2B$7.0B$7.1B
Investments$555.0M$655.0M$626.0M$643.0M$681.0M$705.0M
Operating lease right-of-use assets$449.0M$448.0M$492.0M$495.0M$465.0M$547.0M
Other Assets$39.4B$40.1B$41.6B$42.7B$43.7B$44.4B
Other non-current assets$1.8B$1.8B$1.9B$1.8B$1.9B$2.1B
Property, plant and equipment, net$3.3B——$3.8B$4.0B$4.1B
Property, plant and equipment at cost$6.8B$7.0B$7.2B$7.7B$7.6B$7.7B
Operating Lease Right-of-Use Assets in Other Assets$449.0M$448.0M$492.0M$495.0M$465.0M$547.0M
Accumulated depreciation$3.5B$3.6B$3.8B$3.9B$3.6B$3.7B
Buildings and improvements$2.0B$2.1B$2.2B$2.5B$2.5B$2.5B
Land$144.0M$145.0M$147.0M$147.0M$173.0M$188.0M
Property and equipment, net$3.3B$3.4B$3.5B$3.8B$4.0B$4.1B
Software and Technology Licenses, Net$1.8B$1.8B$1.9B$1.8B$1.9B$2.1B
Total assets$39.4B$40.1B$41.6B$42.7B$43.7B$44.4B

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Aggregate Notional Principal Outstanding$8.6B$10.5B$11.8B$13.1B$13.7B$14.6B
Gross Assets/Liabilities$990.0M$1.0B$1.4B$1.3B$1.3B$1.2B
Allowance for doubtful accounts$109.0M$113.0M$112.0M$133.0M$132.0M$127.0M
Business Combination, Contingent Consideration, Liability$171.0M$214.0M$367.0M$378.0M$385.0M$354.0M
Common stock, par value (in dollars per share)$0.01$0.01$0.01$0.01$0.01$0.01
Common stock, shares authorized (in shares)2B2B2B2B2B2B
Common stock, shares issued (in shares)1.7B1.7B1.7B1.7B1.7B—
Construction work in progress$1.0B$1.0B$1.0B$936.0M$1.2B$1.1B
Contract with Customer, Liability$635.0M$641.0M$662.0M$668.0M$682.0M$686.0M
Short-term debt and current portion of long-term debt$1.8B$777.0M$480.0M$483.0M$299.0M$41.0M
Debt Instrument, Fair Value Disclosure$10.3B$10.9B$11.3B$11.2B$11.2B$10.6B
Deferred income taxes$155.0M$158.0M$226.0M$242.0M$220.0M$219.0M
Derivative, gross, assets$384.0M$232.0M$91.0M$125.0M$181.0M$219.0M
Derivatives, gross, liabilities$990.0M$1.0B$1.4B$1.3B$1.3B$1.2B
Derivative Liability————$1.3B$1.2B
Notional$8.6B$10.5B$11.8B$13.1B$13.7B$14.6B
Equipment, furniture and fixtures$3.6B$3.8B$3.9B$4.0B$3.8B$3.9B
Difference between equity method investment carrying value and book value—$374.0M$321.0M$375.0M—$334.0M
Equity method investments (Note 11)$278.0M$358.0M$334.0M$334.0M$396.0M$309.0M
Trading securities, cost$277.0M$297.0M$292.0M$310.0M$286.0M$396.0M
Current maturities of long-term debt————$1.0M—
Finite-Lived Intangible Assets, Accumulated Amortization$10.6B$10.8B$11.0B$11.2B$11.5B$11.7B
Gross Carrying Amount$17.2B$17.3B$17.4B$17.6B$17.7B$18.0B
Goodwill, Gross$27.0B$27.2B$28.0B$28.1B$28.2B$28.4B
Goodwill accumulated impairment losses$9.9B$9.9B$9.9B$9.9B$9.9B$9.9B
Trademarks$94.0M$94.0M$813.0M$813.0M$813.0M$770.0M
Legal payments remaining to be excluded from calculation of consolidated EBITDA—$1.4B$1.4B$1.4B—$1.1B
Letters of Credit Outstanding, Amount$206.0M$218.0M$220.0M$223.0M$203.0M$193.0M
Licensing arrangements, liability————$7.0M$0.0
Litigation payment exclusion from EBITDA—$1.0B$1.0B$1.0B—$1.2B
Long-Term Debt and Lease Obligation$9.0B$10.5B$11.1B$11.1B$11.1B$11.0B
Loss Contingency Accrual$326.0M$316.0M$300.0M$306.0M$242.0M$229.0M
Noncontrolling interests in subsidiaries$233.0M$233.0M$235.0M$236.0M$239.0M$240.0M
Money Market Funds At Carrying Value————$1.1B$684.0M
Long-Lived Assets$27.5B$27.7B$29.3B$29.7B$29.8B$30.2B
Preferred Stock, Par or Stated Value Per Share$0.01$0.01$0.01$0.01$0.01$0.01
Preferred Stock, Shares Authorized50M50M50M50M50M50M
Preferred Stock, Shares Issued000000
Restricted cash equivalents included in Other long-term assets$80.0M$91.0M$98.0M$103.0M—$119.0M
Share Repurchase Program, Authorized, Amount—————$4.0B
Treasury stock, shares (in shares)263.3M263.3M263.3M263.3M263.3M263.3M
Uncapped Contingent Considertation—$151.0M$106.0M$115.0M—$132.0M
Unrecognized tax benefits$506.0M$514.0M$531.0M$529.0M$596.0M$609.0M
Amount that if recognized, would affect the effective tax rate or regulatory liability$423.0M$431.0M$447.0M$444.0M$501.0M$512.0M

Equity

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accumulated other comprehensive income (loss)$275.0M-$28.0M-$722.0M-$689.0M-$610.0M-$398.0M
Additional paid-in capital$21.1B$21.1B$21.2B$21.4B$21.5B$21.6B
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively$17.0M$17.0M$17.0M$17.0M$17.0M$17.0M
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding$0.0$0.0$0.0$0.0$0.0$0.0
Treasury Stock, Value$2.3B$2.3B$2.3B$2.3B$2.3B$2.3B
Retained earnings$2.7B$3.3B$4.1B$4.9B$5.6B$6.9B
Total liabilities and stockholders' equity$39.4B$40.1B$41.6B$42.7B$43.7B$44.4B
Total stockholders' equity$21.8B$22.2B$22.4B$23.4B$24.2B$25.9B

Non-Current Liabilities

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Long-Term Debt and Finance Lease Obligations$9.0B$10.5B$11.1B$11.1B$11.1B$11.0B
Other non-current liabilities$1.9B$1.9B$2.4B$2.4B$2.4B$2.5B
Total liabilities————$1.7B$1.6B